

REMARKS

The specification has been amended to identify related applications that the present application relies upon for priority.

The above-identified application also is preliminarily amended by canceling originally filed claims 1-17 and adding new claims 18-31. Support for the amendments is found throughout the specification. In particular, support is found in the following passages:

Page 12, lines 18-19
Page 20, lines 26-30
Page 21, lines 4-7
Page 23, lines 18-20
Page 26, line 14
Page 33, lines 29-31
Page 38, lines 15, 31-32
Page 39, l. 10
Page 40, lines 10-13

No new matter is added with these amendments.

No fees are believed to be due. However, if any fees are due in connection with this application, please charge them to our Deposit Account No. 08-0219.

Respectfully submitted,

Date: August 13, 2002

Mary Rose Scozzafava
Mary Rose Scozzafava
Reg. No. 36,268

Hale and Dorr LLP
60 State Street
Boston, MA 02109
Telephone: (617) 526-6015
Facsimile: (617) 526-5000

APPENDIX OF MARKED-UP SPECIFICATION

(and showing changes made)

On page 1, Before the "Field of the Invention," the following paragraph is added.

Related Applications

This application is a continuation application of co-pending application United States Application Serial No. 09/284,297, filed July 5, 2000, which is a § 371 application of International Application No. PCT/US97/18631, filed October 16, 1997, which claims priority to United States Application Serial Nos. 08/729,016, 08/729,344, and 08/729,343, all filed on October 16, 1996.

APPENDIX OF MARKED CLAIMS AFTER AMENDMENT
(and showing changes made)

18. A self-hardening calcium phosphate composite, comprising:
an amorphous calcium phosphate;
a second calcium phosphate having a calcium to phosphate atomic ratio of less than or equal to 1.67, wherein the amorphous calcium phosphate and the second calcium phosphate in combination have a calcium to phosphate atomic ratio in the range of 1.1 to 1.9;
a supplemental material, said supplemental material comprising demineralized bone matrix; and
a carrier fluid in an amount sufficient to form a paste or putty.
19. The composite of claim 18, wherein the amorphous calcium phosphate and the second calcium phosphate in combination have a calcium to phosphate atomic ratio is less than 1.5.
20. The composite of claim 18, wherein the amorphous calcium phosphate has a calcium to phosphate ratio (Ca:P) of about 1.55 to 1.65.
21. The composite of claim 18, wherein the second calcium phosphate is selected from the group consisting of calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium decaphosphate, tricalcium phosphate, monetite, calcium pyrophosphate dihydrate, hydroxyapatite, calcium deficient hydroxyapatite, octacalcium phosphate, and calcium pyrophosphate.
22. The composite of claim 21, wherein the second calcium phosphate comprises , dicalcium phosphate dihydrate.
23. The composite of claim 21, wherein the dicalcium phosphate dihydrate has an average grain size of less than 95 microns.
24. The composite of claim 21, wherein the dicalcium phosphate dihydrate has an average grain size of about 35-45 microns.
25. The composite of claim 18, wherein the amorphous calcium phosphate and second calcium phosphate are present in proportions ranging from 5:1 to 1:5 wt/wt.

26. The composite of claim 18, wherein the carrier fluid is selected from the group consisting of pH buffered solution, saline solution, tissue culture medium and serum.
27. The composite of claim 18, wherein the carrier liquid is present in an amount in the range of about 0.5 mL to about 2.0 mL liquid per gram calcium phosphate.
28. The composite of claim 18, wherein the supplemental material comprises 1 - 50 vol% of the composite.
29. The composite of claim 18, wherein the supplemental material comprises 1-20 vol% of the composite.
30. The composite of claim 18, wherein the supplemental material is in particulate form.
31. The composite of claim 18, wherein the supplemental material is in fiber form.